Skip to main content

Day: December 3, 2019

VAALCO Announces Etame 9H Development Well Has Been Successfully Completed and Placed on Production at Higher Than Anticipated Rate

HOUSTON, Dec. 03, 2019 (GLOBE NEWSWIRE) — VAALCO Energy, Inc. (NYSE: EGY; LSE: EGY) (the Company) today provided an update on its 2019/2020 drilling program Offshore Gabon.HighlightsSuccessfully completed Etame 9H development well including approximately 1,000 feet of horizontal section in Gamba reservoir;Brought onto production at a stabilized flow rate of 5,500 gross barrels of oil per day (BOPD), 1,500 net BOPD to VAALCO, with no H2S;Due to high reservoir quality, production is higher than the  pre-drill estimate of 2,500 to 3,500 BOPD gross, 675  to 960 net  to VAALCO;Increased its forecasted 2019 net exit production rate to 4,500 to 4,700 BOPD, up 16% from its prior estimate of 3,800 to 4,100 BOPD;Expects recategorization of 6.2 million barrels of undeveloped 2P oil reserves to developed 2P oil reserves;Commenced drilling of...

Continue reading

RADA Officially Opens its US Headquarters and Manufacturing Facility in Germantown, Maryland

NETANYA, Israel, Dec. 03, 2019 (GLOBE NEWSWIRE) — RADA Electronic Industries Ltd. (NASDAQ: RADA), a leading provider of advanced tactical radars, announced the grand opening of its new 25,000 square foot US headquarters and manufacturing facility in Germantown, Maryland.RADA’s air surveillance radars are the systems of choice for current and emerging integrated tactical air & missile defense weapon systems, whether based on guns, missiles, directed energy, or other threat defeat technologies. The Company’s radars are ideal “gap-fillers”, complementing medium and long-range air surveillance systems, and work in various installations depending on the mission: fixed, onboard land vehicles and aboard ships.Dov Sella, RADA’s CEO, commented, “We established our US subsidiary, RADA Technologies LLC (RADA USA), in close proximity to...

Continue reading

Emerald Health Therapeutics annonce ses résultats financiers du troisième trimestre 2019 : l’entreprise double son chiffre d’affaires pour un troisième trimestre consécutif

VANCOUVER, Colombie-Britannique, 03 déc. 2019 (GLOBE NEWSWIRE) — Emerald Health Therapeutics, Inc. (« Emerald ») (TSXV: EMH; OTCQX: EMHTF) a présenté ses résultats financiers pour le trimestre et la période de neuf mois terminés le 30 septembre 2019.  Les versions complètes des états financiers consolidés, condensés, intermédiaires non vérifiés de la société et le rapport de gestion pour cette période peuvent être consultées sur le site de SEDAR : www.sedar.com.Faits saillantsEmeraldDoublement des ventes nettes par rapport au trimestre précédent pour atteindre 9,3 M$.Perte nette de 17,5 M$ en raison d’une dévaluation des stocks de 2,8 M$ et d’une diminution de 9,1 M$ des ajustements de juste valeur des actifs biologiques.Frais de vente, généraux et administratifs de 10,1 M$, en baisse par rapport au deuxième trimestre...

Continue reading

ASLAN Pharmaceuticals Announces Pricing of $12.8 Million Public Offering of American Depositary Shares

SINGAPORE, Dec. 03, 2019 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals Limited (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that it has priced its previously announced underwritten public offering of 5,124,527 American Depositary Shares (“ADSs”) at a public offering price of $2.50 per ADS. Each ADS represents five ordinary shares of ASLAN. The gross proceeds to ASLAN, before deducting underwriting discounts, commissions and other offering expenses, are expected to be approximately $12.8 million. All of the ADSs in the offering are being sold by ASLAN. In addition, ASLAN has granted the underwriter an option, exercisable at any time through and until one day before the closing date of this offering, to purchase up to an additional 768,679 ADSs at the public offering price,...

Continue reading

Notice on Public Offering of Subordinated Bonds of AS Inbank

ANNOUNCEMENT3 December 2019Inbank ASNotice on Public Offering of Subordinated Bonds of AS InbankAS Inbank  (registry code 12001988, registered address Niine tn 11, Tallinn 10414, Estonia; hereinafter Inbank) hereby announces a public offering of Inbank subordinated bonds.“We are conducting our next issue of bonds on the Nasdaq Tallinn Stock Exchange,  Baltic Bond List in order to expand Inbank’s investor base and bring an attractive investment opportunity to the Estonian market. The funds will be used to support Inbank’s growth and expansion in foreign markets,” said Priit Põldoja, Chairman of the Supervisory Board of Inbank.Public Offering of Subordinated BondsInbank offers publicly 6,500 subordinated bonds ”Inbank subordinated bond 19.12.2029” with the nominal value of EUR 1,000, interest rate offered of 6.0% per annum...

Continue reading

AS Inbank allutatud võlakirjade avaliku pakkumise teade

BÖRSITEADE3.12.2019Inbank AS AS Inbank allutatud võlakirjade avaliku pakkumise teadeAS Inbank  (registrikood 12001988, registreeritud aadress Niine tn 11, Tallinn 10414, Eesti; edaspidi Inbank) kuulutab käesolevaga välja Inbanki allutatud võlakirjade avaliku pakkumise.“Teeme järjekordse emissiooni Nasdaqi Balti võlakirjade turule, et laiendada Inbanki investorbaasi ja tuua Eesti turule atraktiivne investeerimisvõimalus. Emissioonist saadavaid vahendeid kasutame Inbanki kasvu toetamiseks ning laienemiseks välisturgudel,” lausus Inbanki nõukogu esimees Priit Põldoja.Allutatud võlakirjade avalik pakkumineInbank pakub avalikult 6500 allutatud võlakirja „Inbanki allutatud võlakiri 19.12.2029“ nimiväärtusega 1000 eurot, investorile pakutava intressimääraga 6,0% aastas ja lunastustähtajaga 19.12.2029. Inbankil on kuni emissioonikuupäevani...

Continue reading

9F Inc. to Report Third Quarter 2019 Financial Results on December 5, 2019

BEIJING, Dec. 02, 2019 (GLOBE NEWSWIRE) — 9F Inc. (“9F” or “the Company”) (NASDAQ: JFU), a leading digital financial account platform integrating and personalizing financial services in China, today announced that it will release its unaudited financial results for the third quarter ended September 30, 2019, before the open of U.S. markets on Thursday, December 5, 2019.The Company’s management will host an earnings conference call at 8:00 AM U.S. Eastern Time on December 5, 2019 (9:00 PM Beijing / Hong Kong Time on the same day).Dial-in details for the earnings conference call are as follows:Please dial in ten minutes before the call is scheduled to begin and provide the passcode to join the call.Additionally, a live and archived webcast of the conference call will be available on the Company’s investor relations website at http://ir.9fgroup.com.About...

Continue reading

Clearway Energy, Inc. Announces Pricing of Offering of Class C Common Stock

PRINCETON, N.J., Dec. 02, 2019 (GLOBE NEWSWIRE) —  Clearway Energy, Inc. (NYSE: CWEN, CWEN.A) (“Clearway Energy”) today announced that it has priced the previously announced underwritten public offering of 5,405,405 shares of its Class C common stock at a price of $18.70 per share.Clearway Energy intends to use the net proceeds from the offering to acquire newly issued Class C units of Clearway Energy LLC (“Clearway LLC”).  Clearway Energy intends to cause Clearway LLC to use such proceeds to partially fund the acquisition of the 527 megawatt Carlsbad Energy Center from an affiliate of Global Infrastructure Partners III (“GIP”), pay transaction fees and expenses and use the balance of the proceeds, if any, for general corporate purposes.RBC Capital Markets, LLC is acting as the sole book runner for the offering.A shelf registration...

Continue reading

Hemostemix Announces Appointment of Director and Postponement of Annual and Special Meeting

CALGARY, Alberta, Dec. 02, 2019 (GLOBE NEWSWIRE) — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTC: HMTXF), a biotechnology company focused on developing and commercializing innovative blood-derived stem cell therapies for medical conditions not adequately addressed by current treatments, announces the appointment of Mr. Bryson Goodwin as a director of the Company (“the “Board”) effective December 2, 2019, subject to customary TSX Venture Exchange (“TSXV”) approval.Mr. Goodwin is a practiced international executive with extensive experience in finance, sales, management, investor relations and operations with both private and public companies. Bryson’s experience has demonstrated an operational, market and banking track record in the technology, biotechnology and resource sectors. Over the course of Mr. Goodwin’s...

Continue reading

Ascent Announces CCAA Creditors’ Meeting Order and Bi-Weekly Default Status Report

VANCOUVER, British Columbia, Dec. 02, 2019 (GLOBE NEWSWIRE) — Ascent Industries Corp. (CSE: ASNT) (“Ascent” or the “Company”) announces that the Company and certain of its affiliates (collectively, the “Applicants”) obtained an order on November 22, 2019 (the “Meeting Order”) from the Supreme Court of British Columbia (the “Court”): (i) accepting the filing of a consolidated plan of compromise, arrangement and reorganization under the Companies’ Creditors Arrangement Act (“CCAA”) by the Applicants (the “Plan”); (ii) authorizing the Applicants to establish one class of Affected Creditors (as defined in the Plan) in the Plan for the purposes of considering and voting on the Plan; (iii) authorizing and directing the Applicants to call, hold and conduct a meeting of Affected Creditors (the “Creditors’ Meeting“) to consider...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.